Our top pick for
uniQure N.V is a biotechnology business based in the US. uniQure N-V shares (QURE) are listed on the NASDAQ and all prices are listed in US Dollars. uniQure N-V employs 332 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$29.36|
|52-week range||$25.80 - $52.19|
|50-day moving average||$32.79|
|200-day moving average||$31.70|
|Wall St. target price||$66.09|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$6.65|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-19)||2.91%|
|1 month (2021-09-24)||-13.06%|
|3 months (2021-07-26)||8.70%|
|6 months (2021-04-26)||-15.99%|
|1 year (2020-10-26)||-32.43%|
|2 years (2019-10-25)||-40.60%|
|3 years (2018-10-26)||13.67%|
|5 years (2016-10-26)||320.63%|
Valuing uniQure N-V stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of uniQure N-V's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
uniQure N-V's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 4x. In other words, uniQure N-V shares trade at around 4x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
uniQure N-V's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $307.3 million.
The EBITDA is a measure of a uniQure N-V's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$500.2 million|
|Operating margin TTM||59.28%|
|Gross profit TTM||$-84,886,000|
|Return on assets TTM||31.69%|
|Return on equity TTM||67.5%|
|Market capitalisation||$1.3 billion|
TTM: trailing 12 months
There are currently 2.9 million uniQure N-V shares held short by investors – that's known as uniQure N-V's "short interest". This figure is 43.7% up from 2.0 million last month.
There are a few different ways that this level of interest in shorting uniQure N-V shares can be evaluated.
uniQure N-V's "short interest ratio" (SIR) is the quantity of uniQure N-V shares currently shorted divided by the average quantity of uniQure N-V shares traded daily (recently around 1.0 million). uniQure N-V's SIR currently stands at 2.81. In other words for every 100,000 uniQure N-V shares traded daily on the market, roughly 2810 shares are currently held short.
However uniQure N-V's short interest can also be evaluated against the total number of uniQure N-V shares, or, against the total number of tradable uniQure N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case uniQure N-V's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 uniQure N-V shares in existence, roughly 60 shares are currently held short) or 0.0625% of the tradable shares (for every 100,000 tradable uniQure N-V shares, roughly 63 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against uniQure N-V.
Find out more about how you can short uniQure N-V stock.
We're not expecting uniQure N-V to pay a dividend over the next 12 months.
uniQure N-V's shares were split on a 1:5 basis on 30 January 2014. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your uniQure N-V shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for uniQure N-V shares which in turn could have impacted uniQure N-V's share price.
Over the last 12 months, uniQure N-V's shares have ranged in value from as little as $25.8 up to $52.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while uniQure N-V's is 1.1307. This would suggest that uniQure N-V's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
uniQure N. V. , a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated virus (AAV) 5-based gene therapy for the treatment of Fabry disease; and AMT-150, a one-time, intrathecally-administered, AAV gene therapy for treating spinocerebellar ataxia type 3. The company has collaboration and license agreements with Bristol Myers-Squibb Company; Gen-X; and Synpromics Limited. uniQure N.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.